The Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections by ten companies/universities/institutes. The top development phase for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections is preclinical with three drugs in that stage. The Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline has seven drugs in development by companies and three by universities/ institutes. Some of the companies in the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline products market are: University of Tennessee Research Foundation, LigaChem Biosciences and Debiopharm International.
The key targets in the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline products market include Penicillin Binding Protein 2a, Peptidoglycan, and Undecaprenyl-Phosphate N-Acetylglucosaminyl 1-Phosphate Transferase.
The key mechanisms of action in the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline product include Peptidoglycan Inhibitor with one drug in Phase I. The Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline products include five routes of administration with the top ROA being Oral and three key molecule types in the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline products market including Small Molecule, and Synthetic Peptide.
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections overview
Methicillin-susceptible Staphylococcus aureus (MSSA) is a bacterium that is resistant to many antibiotics. MSSA usually causes skin infections, but can also cause pneumonia and other serious types of infections. Symptoms include cellulitis, painful rashes, nausea and vomiting, fever, muscle aches, diarrhea, and abdominal pain. Predisposing factors include weakened immune systems, burns, and surgical wounds.
For a complete picture of Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
